OC-PF-treated animal sera showed significant reduction in the PSA level compared to in the mice treated with the placebo control, highlighting the potential of OC as a prospective, novel, small-molecule PC recurrence suppressor via modulating SMYD2 expression level. This evidence concerns the gene SMYD2 and pachyonychia congenita.